B of A Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $125

Benzinga Newsdesk www.benzinga.com Positive 86.7%

Neg 0% Neu 0% Pos 86.7%

B of A Securities analyst Tazeen Ahmad maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $110 to $125.